메뉴 건너뛰기




Volumn 13, Issue 3, 2017, Pages 613-620

Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia

(36)  Dolzhikova, I V a   Zubkova, O V a   Tukhvatulin, A I a   Dzharullaeva, A S a   Tukhvatulina, N M a   Shcheblyakov, D V a   Shmarov, M M a   Tokarskaya, E A a   Simakova, Y V a   Egorova, D A a   Scherbinin, D N a   Tutykhina, I L a   Lysenko, A A a   Kostarnoy, A V a   Gancheva, P G a   Ozharovskaya, T A a   Belugin, B V a   Kolobukhina, L V a   Pantyukhov, V B b   Syromyatnikova, S I b   more..


Author keywords

Ad5; Ebola; Ebola virus disease; heterologous vaccination; prime boost; vaccine; VSV; ZEBOV

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; CREATININE; EBOLA VACCINE; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; VIRUS GLYCOPROTEIN; DRUG CARRIER; RECOMBINANT VACCINE; VIRUS ANTIBODY;

EID: 85011579453     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2016.1238535     Document Type: Article
Times cited : (95)

References (23)
  • 1
    • 34548512432 scopus 로고    scopus 로고
    • Filoviridae: Marburg and Ebola viruses
    • Knipe D.M., Howley P.M., Griffin D.E., Lamb R.A., Martin M.A., Roizman B., Straus S.E., (eds), editors, Philadelphia (PA: Lippincott Williams & Wilkins
    • Sanchez A, Geisbert TW, Feldmann H. Filoviridae:Marburg and Ebola viruses. In:Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE, editors. Fields virology fifth edition volume 1. Philadelphia (PA):Lippincott Williams & Wilkins; 2007, p. 1409-48.
    • (2007) Fields virology fifth edition volume 1 , pp. 1409-1448
    • Sanchez, A.1    Geisbert, T.W.2    Feldmann, H.3
  • 2
    • 77953665114 scopus 로고    scopus 로고
    • Filoviruses are ancient and integrated into mammalian genomes
    • 20569424
    • Taylor DJ, Leach RW, Bruenn J. Filoviruses are ancient and integrated into mammalian genomes. BMC Evol Biol 2010; 10:193; PMID:20569424; http://dx.doi.org/10.1186/1471-2148-10-193
    • (2010) BMC Evol Biol , vol.10 , pp. 193
    • Taylor, D.J.1    Leach, R.W.2    Bruenn, J.3
  • 4
    • 85015293662 scopus 로고    scopus 로고
    • Geneva (Switzerland: World Health Organization, Oct
    • World Health Organization. Ebola situation report-21 October 2015. Geneva (Switzerland):World Health Organization; 2015Oct21. http://apps.who.int/ebola/current-situation/ebola-situation-report-21-october-2015#main-content
    • Ebola situation report-21 October 2015
  • 5
    • 85050578622 scopus 로고    scopus 로고
    • Clinical development of Ebola vaccines
    • 26668751
    • Sridhar S. Clinical development of Ebola vaccines. Ther Adv Vaccines 2015; 3(5–6):125-38; PMID:26668751; http://dx.doi.org/10.1177/2051013615611017
    • (2015) Ther Adv Vaccines , vol.3 , Issue.5-6 , pp. 125-138
    • Sridhar, S.1
  • 8
    • 0019194453 scopus 로고
    • Inactivated vaccine for Ebola virus efficacious in guineapig model
    • 6108462
    • Lupton HW, Lambert RD, Bumgardner DL, Moe JB, Eddy GA. Inactivated vaccine for Ebola virus efficacious in guineapig model. Lancet 1980; 2(8207):1294-5; PMID:6108462; http://dx.doi.org/10.1016/S0140-6736(80)92352-1
    • (1980) Lancet , vol.2 , Issue.8207 , pp. 1294-1295
    • Lupton, H.W.1    Lambert, R.D.2    Bumgardner, D.L.3    Moe, J.B.4    Eddy, G.A.5
  • 9
    • 84934286956 scopus 로고    scopus 로고
    • Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial
    • 25817373
    • Zhu FC, Hou LH, Li JX, Wu SP, Liu P, Zhang GR, Hu YM, Meng FY, Xu JJ, Tang R, et al. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China:preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet 2015; 385(9984):2272-9; PMID:25817373; http://dx.doi.org/10.1016/S0140-6736(15)60553-0
    • (2015) Lancet , vol.385 , Issue.9984 , pp. 2272-2279
    • Zhu, F.C.1    Hou, L.H.2    Li, J.X.3    Wu, S.P.4    Liu, P.5    Zhang, G.R.6    Hu, Y.M.7    Meng, F.Y.8    Xu, J.J.9    Tang, R.10
  • 10
    • 84940952795 scopus 로고    scopus 로고
    • Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial
    • 26248676
    • Henao-Restrepo AM, Longini IM, Egger M, Dean NE, Edmunds WJ, Camacho A, Carroll MW, Doumbia M, Draguez B, Duraffour S, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein:interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 2015; 386(9996):857-66; PMID:26248676; http://dx.doi.org/10.1016/S0140-6736(15)61117-5
    • (2015) Lancet , vol.386 , Issue.9996 , pp. 857-866
    • Henao-Restrepo, A.M.1    Longini, I.M.2    Egger, M.3    Dean, N.E.4    Edmunds, W.J.5    Camacho, A.6    Carroll, M.W.7    Doumbia, M.8    Draguez, B.9    Duraffour, S.10
  • 11
    • 84942194673 scopus 로고    scopus 로고
    • The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial
    • 26248510
    • Huttner A, Dayer JA, Yerly S, Combescure C, Auderset F, Desmeules J, Eickmann M, Finckh A, Goncalves AR, Hooper JW, et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine:a randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect Dis 2015; 15(10):1156-66; PMID:26248510; http://dx.doi.org/10.1016/S1473-3099(15)00154-1
    • (2015) Lancet Infect Dis , vol.15 , Issue.10 , pp. 1156-1166
    • Huttner, A.1    Dayer, J.A.2    Yerly, S.3    Combescure, C.4    Auderset, F.5    Desmeules, J.6    Eickmann, M.7    Finckh, A.8    Goncalves, A.R.9    Hooper, J.W.10
  • 12
    • 84959184825 scopus 로고    scopus 로고
    • Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial
    • 26546548
    • Tapia MD, Sow SO, Lyke KE, Haidara FC, Diallo F, Doumbia M, Traore A, Coulibaly F, Kodio M, Onwuchekwa U, et al. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo:a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 2016; 16(1):31-42; PMID:26546548; http://dx.doi.org/10.1016/S1473-3099(15)00362-X
    • (2016) Lancet Infect Dis , vol.16 , Issue.1 , pp. 31-42
    • Tapia, M.D.1    Sow, S.O.2    Lyke, K.E.3    Haidara, F.C.4    Diallo, F.5    Doumbia, M.6    Traore, A.7    Coulibaly, F.8    Kodio, M.9    Onwuchekwa, U.10
  • 13
    • 84959245846 scopus 로고    scopus 로고
    • Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study
    • 26725450
    • De Santis O, Audran R, Pothin E, Warpelin-Decrausaz L, Vallotton L, Wuerzner G, Cochet C, Estoppey D, Steiner-Monard V, Lonchampt S, et al. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults:a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect Dis 2016; 16(3):311-20; PMID:26725450; http://dx.doi.org/10.1016/S1473-3099(15)00486-7
    • (2016) Lancet Infect Dis , vol.16 , Issue.3 , pp. 311-320
    • De Santis, O.1    Audran, R.2    Pothin, E.3    Warpelin-Decrausaz, L.4    Vallotton, L.5    Wuerzner, G.6    Cochet, C.7    Estoppey, D.8    Steiner-Monard, V.9    Lonchampt, S.10
  • 15
    • 84939809433 scopus 로고    scopus 로고
    • Chimpanzee adenovirus vector Ebola vaccine–preliminary report
    • 26287857
    • Ledgerwood JE, Sullivan NJ, Graham BS. Chimpanzee adenovirus vector Ebola vaccine–preliminary report. N Engl J Med 2015; 373(8):776; PMID:26287857
    • (2015) N Engl J Med , vol.373 , Issue.8 , pp. 776
    • Ledgerwood, J.E.1    Sullivan, N.J.2    Graham, B.S.3
  • 16
    • 85011081815 scopus 로고    scopus 로고
    • A Recombinant Vesicular Stomatitis Virus Ebola Vaccine—Preliminary Report
    • 25830322
    • Regules JA, Beigel JH, Paolino KM, Voell J, Castellano AR, Munoz P, et al. A Recombinant Vesicular Stomatitis Virus Ebola Vaccine—Preliminary Report. N Engl J Med 2015; PMID:25830322; http://dx.doi.org/10.1056/NEJMoa1414216
    • (2015) N Engl J Med
    • Regules, J.A.1    Beigel, J.H.2    Paolino, K.M.3    Voell, J.4    Castellano, A.R.5    Munoz, P.6
  • 19
    • 78649703575 scopus 로고    scopus 로고
    • A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults
    • 21034824
    • Ledgerwood JE, Costner P, Desai N, Holman L, Enama ME, Yamshchikov G, Mulangu S, Hu Z, Andrews CA, Sheets RA, et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 2010; 29(2):304-13; PMID:21034824; http://dx.doi.org/10.1016/j.vaccine.2010.10.037
    • (2010) Vaccine , vol.29 , Issue.2 , pp. 304-313
    • Ledgerwood, J.E.1    Costner, P.2    Desai, N.3    Holman, L.4    Enama, M.E.5    Yamshchikov, G.6    Mulangu, S.7    Hu, Z.8    Andrews, C.A.9    Sheets, R.A.10
  • 21
    • 77955511003 scopus 로고    scopus 로고
    • Atlanta (GA: Centers for Disease Control and Prevention, Jul
    • Centers for Disease Control and Prevention. Possible side-effects from vaccines. Atlanta (GA):Centers for Disease Control and Prevention; 20 Jul 2016. http://www.cdc.gov/vaccines/vac-gen/side-effects.htm
    • (2016) Possible side-effects from vaccines
  • 22
    • 37649021448 scopus 로고    scopus 로고
    • Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester
    • 17853860
    • Quah BJ, Warren HS, Parish CR. Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester. Nat Protoc 2007; 2(9):2049-56; PMID:17853860; http://dx.doi.org/10.1038/nprot.2007.296
    • (2007) Nat Protoc , vol.2 , Issue.9 , pp. 2049-2056
    • Quah, B.J.1    Warren, H.S.2    Parish, C.R.3
  • 23
    • 84969513575 scopus 로고    scopus 로고
    • Powerful complex immunoadjuvant based on synergistic effect of combined TLR4 and NOD2 activation significantly enhances magnitude of humoral and cellular adaptive immune responses
    • 27187797
    • Tukhvatulin AI, Dzharullaeva AS, Tukhvatulina NM, Shcheblyakov DV, Shmarov MM, Dolzhikova IV, Stanhope-Baker P, Naroditsky BS, Gudkov AV, Logunov DY, et al. Powerful complex immunoadjuvant based on synergistic effect of combined TLR4 and NOD2 activation significantly enhances magnitude of humoral and cellular adaptive immune responses. PLoS One 2016 11(5):e0155650; PMID:27187797; http://dx.doi.org/10.1371/journal.pone.0155650
    • (2016) PLoS One , vol.11 , Issue.5 , pp. 155650
    • Tukhvatulin, A.I.1    Dzharullaeva, A.S.2    Tukhvatulina, N.M.3    Shcheblyakov, D.V.4    Shmarov, M.M.5    Dolzhikova, I.V.6    Stanhope-Baker, P.7    Naroditsky, B.S.8    Gudkov, A.V.9    Logunov, D.Y.10


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.